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Abstract: The detection of cancer antigens is a major aim of cancer research in order to develop better
patient management through early disease detection. Many cancers including prostate, lung, and
ovarian secrete a protein disulfide isomerase protein named AGR2 that has been previously detected
in urine and plasma using mass spectrometry. Here we determine whether a previously developed
monoclonal antibody targeting AGR2 can be adapted from an indirect two-site ELISA format into
a direct detector using solid-phase printed gold electrodes. The screen-printed gold electrode
was surface functionalized with the anti-AGR2 specific monoclonal antibody. The interaction of
the recombinant AGR2 protein and the anti-AGR2 monoclonal antibody functionalized electrode
changed its electrochemical impedance spectra. Nyquist diagrams were obtained after incubation in
an increasing concentration of purified AGR2 protein with a range of concentrations from 0.01 fg/mL
to 10 fg/mL. In addition, detection of the AGR2 antigen can be achieved from cell lysates in medium
or artificial buffer. These data highlight the utility of an AGR2-specific monoclonal antibody that
can be functionalized onto a gold printed electrode for a one-step capture and quantitation of the
target antigen. These platforms have the potential for supporting methodologies using more complex
bodily fluids including plasma and urine for improved cancer diagnostics.
Keywords: AGR2 protein; sensor; screen-printed gold electrode; electrochemical impedance spectroscopy
1. Introduction
Anterior Gradient-2 (AGR2) was identified as a key protein involved in the assem-
bly of the dorso–anterior ectoderm that forms the cement gland and maintains forebrain
integrity [1,2]. AGR2 has since been shown to be an endoplasmic reticulum (ER) local-
ized protein disulfide isomerase superfamily member [3] that is upregulated in a large
number of human cancers [4,5]. The cancer associated functions of AGR2 have been in-
ferred from several lines of research including (i) AGR2 drives cement gland production,
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whose function promotes the attachment of the growing epithelium to a solid support [6],
(ii) AGR2 can mediate metastatic growth in cancer models [7], and (iii) AGR2 can mediate
limb regeneration in amphibia [8]. AGR2 has also been implicated in a diverse range of
diseases including asthma [9] and inflammatory bowel disease [10].
AGR2 is over-expressed in a diverse set of human cancers including breast [11],
prostate [12], pancreatic [13], liver [14], ovarian [15], esophagus [16–18], and lung can-
cers [19]. In some cases, AGR2 is secreted allowing remodeling of the pro-metastatic
niche [20,21]. Accordingly, mass spectrometry and ELISA methodologies have been used
to detect AGR2 peptide fragments in urine or plasma [22–26]. In addition to this diagnostic
potential of AGR2, inhibition of extracellular AGR2 function using antibodies or peptides
suggests therapeutic tools can be developed [27–29]. The range of AGR2 concentrations
associated with cancer has been described by Edgell et al. [26]. The paper shows signifi-
cantly increased concentrations of AGR2 protein in plasma from cancer patients relative
to normal controls. Plasma AGR2 concentrations were highest in stages II and III ovarian
cancer patients and were similarly elevated in patients with both serous and non-serous
tumors. The identification of elevated plasma concentrations of AGR2 may provide a useful
biomarker to aid in the discrimination of normal and ovarian cancer patients particularly.
In order to develop new diagnostic assays for AGR2, we had developed a panel of
monoclonal antibodies or aptamers that can detect AGR2 and its orthologue AGR3 [15].
These antibodies were functionalized using fluorescent conjugation to develop a two-
site ELISA that measures the capture of dimeric AGR2 [30,31]. However, these mass
spectrometry approaches and ELISA approaches are limited for rapid diagnostics; the mass
spectrometry assay requires significant instrumentation time, costs, and sample preparation
whilst the ELISA is a two-step process involving antigen capture and antigen detection.
A novel diagnostic platform has been developed using a gold biosensor that enables
the specific detection of a specific antigen at ultralow concentrations using a ‘one-step’
methodology; a screen-printed gold electrode is surface functionalized with the antibodies
of interest and after the absorption of the target antigen, a change in the electrochemical
impedance spectra is measured as a function of different features with a limit of detection
of 9.3 cfu/mL defined for a bacterial biomarker [32]. In this report, we aimed to use a
gold electrode platform [33] to determine whether the AGR2 antigen can be detected in
a ‘one-step’ process from aqueous samples using the monoclonal antibody validated in
clinical tissue using immunohistochemistry [15] and in a two-site ELISA assay [31]. Our
data demonstrate that the gold electrode can detect femtogram levels of AGR2 protein
in vitro cell culture systems and highlights a platform for further evaluation of AGR2 in
liquid biopsies.
2. Materials and Methods
2.1. Reagents and Materials
For the preparation and modification of electrodes, 99.8% Ethanol and Sulfuric Acid
were provided by Chempur (Piekary Śląskie, Poland); Phosphate-Buffered Saline (PBS)
tablets, Tris Buffered Saline (TBS), 97% 4-ATP, 25% GA, and Bovine Serum Albumin (BSA)
were provided by Sigma Aldrich (Munich, Germany).
2.2. Electrochemical Procedures
The cyclic voltammetry and electrochemical impedance spectroscopy (EIS) were
conducted using a Palmsens4 potentiostat/galvanostat system (PalmSens, Houten, The
Netherlands) in the standard three electrode configuration. Gold screen-printed electrodes
(DropSens, Asturias, Spain) were used as working electrodes, the Pt mesh was used as
a counter electrode, while Ag/AgCl/0.1 M KCl was used as a reference electrode. All
the electrochemical tests were carried out in 1 mM K3[Fe(CN)6]/K4[Fe(CN)6]/0.1 M PBS
that was previously deaerated. CV data were collected in the voltage window of −0.65 to
+0.75 V at the scan rate of 100 mV/s, always in triplicate.
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In case of the electrochemical impedance spectroscopy measurements (EIS), the fre-
quency ranged from 100 kHz to 0.1 Hz with 50 points. The amplitude of the AC signal
was 10 mV. Obtained impedance spectra were recorded at the redox reaction formal po-
tential (EF). EF value was calculated based on the redox peaks’ positions present on the
CV voltammograms for the screen-printed electrode and approximately equaled 150 mV.
Each potential was held constant for 60 s before each measurement to obtain a steady-state
condition. Obtained data were subjected to the analysis using an EIS Spectrum Analyzer
according to the proposed electric equivalent circuit (EEQC).
2.3. Biomaterials Preparation and Identification by Reference Methods
AGR2 protein was purified as reported previously [18]. A549 cells were grown, and
lysates made as described previously (see Supplementary, Figure S1) [34]. The AGR2-
monoclonal antibody was purified using Protein A columns and stored in PBS at a temper-
ature of 4 ◦C, as described previously [15,31]. The incubation time of the electrode with the
target solution was 5 min for both the positive and negative samples. The H1299 non-small
cell lung carcinoma cell line was from ATCC®®, Manassas, VA, USA—CRL-5803™. The
cells were maintained in standard culture conditions (37 ◦C, humidified atmosphere and
5% CO2) in high glucose Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, St.
Louis, MO, USA) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific,
Waltham, MA, USA), 1% sodium pyruvate (Sigma-Aldrich), and a penicillin/streptomycin
antibiotic mixture (Biosera, Nuaille, France).
2.4. Preparation of the Immunosensor
The gold electrodes were cleaned with 0.5 M H2SO4 for 15 min. After each treatment,
the gold substrates were rinsed with ethanol and dried under nitrogen flow. Then, the
pre-treated gold electrodes were immersed in 0.1 M 4-aminothiophenol in ethanol solution
for 12 h in order to form a self-assembled monolayer (SAM). The substrates were then
rinsed with ethanol in order to remove the unbonded thiols. To allow antibodies to attach,
the thiol-modified electrodes were treated with 2.5% glutaraldehyde for 15 min in a dark
place. Next, the gold electrodes were rinsed with water and dried under nitrogen and
10 µg/µL of the anti-AGR2 IgG was dropped onto the surface at 37 ◦C for 1 h. The excess
antibodies were removed by rinsing with PBS. Then, the antibody-modified electrodes
were treated with 0.1% BSA for 30 min, to block the unreacted and non-specific sites. After
rinsing with PBS and water, the electrodes were dried under nitrogen. The mechanism for
this activation can be seen in Figure 1.
Biosensors 2021, 11, x FOR PEER REVIEW 4 of 12 
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decrease in the electron transfer rate. This was due to an increase in the biolayer thickness 
that was developed on gold surface. The cyclic voltammograms are strongly affected by 
the deposited layers, the difference between the anodic and cathodic peak potentials does 
not remain constant, whereas the peak current is modified significantly. The initial char-
acteristic quasi-reversible redox cycle for a bare gold electrode can be seen. After its func-
tionalization with BSA, the electron transfer between the redox probe and electrode sur-
face was severely affected and an obvious decrease of the anodic and cathodic peaks was 
observed. 
After anti-AGR2 IgG immobilization on the functionalized electrode surface, the 
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reaction of protein AGR2 molecules with the antibody film revealed a decrease in the Far-
adaic response. An increase was observed in the peak-to-peak separation between the ca-
thodic and anodic waves of the redox probe, indicating that the electron-transfer kinetics 
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Figures 2B and 3A show the impedance spectra recorded with the EIS technique for 
a pure gold electrode and after each stage of the modification of its surface and during the 
detection of the AGR2 protein, respectively. The shape of the impedance spectra in the 
tested measuring frequency range from 100 kHz to 0.1 Hz is identical. The EIS spectra 
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for glutaraldehy , anti-AGR2 is for the AGR2 antibody, and for bovine serum albumin.
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3. Results
3.1. Characterization of the Modified Electrode
For the electrochemical measurements, the CV was recorded before and after the
deposition of the 4-ATP monolayer. In Figure 2, the Fe(II)/Fe(III) redox peaks exhibit
decreased signals after the functionalization of the 4-ATP monolayer. This can be attributed
to a decrease in the electron transfer rate that was created by the compactness of the
formulated SAMs. After antibody binding, the redox peaks decreased even more due
to the decrease in the electron transfer rate. This was due to an increase in the biolayer
thickness that was developed on gold surface. The cyclic voltammograms are strongly
affected by the deposited layers, the difference between the anodic and cathodic peak
potentials does not remain constant, whereas the peak current is modified significantly.
The initial characteristic quasi-reversible redox cycle for a bare gold electrode can be seen.
After its functionalization with BSA, the electron transfer between the redox probe and
electrode surface was severely affected and an obvious decrease of the anodic and cathodic
peaks was observed.
Biosensors 2021, 11, x FOR PEER REVIEW 5 of 12 
 
 
Figure 2. CV (A) and EIS (B) plots recorded for bare and modified Au electrode in 1 mM Fe(CN)63-/4-/0.1 M PBS with scan 
rate 50 mV/s. 
 
Figure 3. EIS measurement of biosensor response in time, after BSA modification. Registered in 1 
mM K3[Fe(CN)6]/K4[Fe(CN)6]/0.01 M PBS. 
For the analysis of the impedance spectra, the electrical equivalent circuit represented 
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the constant phase element (represented by Q and n), Rct is the charge transfer resistance, 
and W is the Warburg impedance. The electrical equivalent circuit in the form of a Randles 
circuit is one of the basic models for describing the electrochemical processes occurring at 
the electrode/electrolyte interface. It is also widely used for impedance data analysis in 
electrochemical sensor/biosensor research [33,36–38]. 
Comparing the spectra recorded for bare screen-printed gold electrode, antibody-
modified surface, and after saturation with a BSA solution, we observed a significant in-
crease in resistance Rct values. Such an increase in Rct suggests successful binding between 
antigen and bare gold surface followed by unspecific binding of BSA to the modified gold 
substrate. 
Stability analysis for the fully functionalized sensor can be seen in Figure 3. The BSA 
concentration was kept in the same order of magnitude to receive comparable results and 
i . fi l tr i e( )63−/4−/0.1 M PBS with
scan rate 50 mV/s.
After anti-AGR2 IgG immobilization on the functionalized electrode surface, the peak
currents of the redox couple of ferricyanide/ferrocyanide decrease. Immunochemical
reaction of protein AGR2 molecules with the antibody film revealed a decrease in the
Faradaic response. An increase was observed in the peak-to-peak separation between the
cathodic and anodic waves of the redox probe, indicating that the electron-transfer kinetics
of ferricyanide/ferrocyanide was obstructed.
Figures 2B and 3A show the impedance spectra recorded with the EIS technique for
a pure gold electrode and after each stage of the modification of its surface and during
the detection of the AGR2 protein, respectively. The shape of the impedance spectra in
the tested measuring frequency range from 100 kHz to 0.1 Hz is identical. The EIS spectra
consists of one time constant. In the range of the highest and intermediate measurement
frequencies, there is a capacitive loop, while at the lowest measurement frequencies,
its presence is manifested by the Warburg impedance associated with diffusion control
(straight line inclined at an angle of 45◦ to the X-axis).
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Figure 3. EIS measurement of biosensor response in time, after BSA modification. Registered in
1 mM K3[Fe(CN)6]/K4[Fe(CN)6]/0.01 M PBS.
For the analysis of the impedance spectra, the electrical equivalent circuit represented
by the Randles circuit Re(CPE[RctW]) [35] was used. Re is the electrolyte resistance, CPE is
the constant pha e element (represented by Q and n), Rct is the charge transfer resis anc ,
and W is the Warburg impedance. The electrical equivalent circuit in the form of a Randles
circuit is one of the basic models for describing the electrochemical processes occurring at
the electrode/electrolyte interface. It is also widely used for impedance data analysis in
electrochemical sensor/biosensor research [33,36–38].
Comparing the spectra recorded for bare screen-printed gol electrode, antibody-
modified surface, and after saturation with a BSA solution, we observed a significant
increase in resistance Rct values. Such an increase in Rct suggests successful binding
between antigen and bare gold surface followed by unspecific binding of BSA to the
modified gold substrate.
Stability analysis for the fully functionalized sensor can be seen in Figure 3. The BSA
concentration was kept in the sam order of magnit de to receive comparable resul s and
impedance spectra were recorded in time. The sensor response was checked in time cycles
of 1, 3, and 5 min.
3.2. Impedance Measurem nts for the Detection of the AGR2 Protein
The next stage of verification of the modified screen-printed gold electrode as a
potential biosensor includes subsequent incubation in diluted solution of AGR2 protein and
recording the electrode response with electrochemical impedance spectroscopy (Figure 4A).
Here, the charge transfer resistance (Rct) increases gradually as the protein concentration
increases after consecutive incubations. This was made from 0.01 fg/mL to 1 fg/mL.
Table 1 presents the resistance values with incubation.
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Figure 4B displays the impedance changes for the developed immunosensor incubated
with different AGR2 protein concentrations. The tested gold impedance immunosensor was
characterized by a linear response from 0.001 fg/mL to 0.900 fg/mL. The linear regression
equation can be expressed as ∆Rct[%] = 127.5 CAGR2protein[fg/mL] + 41.44 with a correlation
coefficient of R2 = 0.97. The values of relative standard deviation were calculated and
ranged from 4.3% to 6.9%. The sensitivity is 127.5%(fg/mL)−1. The obtained limit of
detection (LOD) for the presented immunosensor equals 0.093 fg/mL (S/N = 3). Linearity
ranges and LODs of different methods for AGR2 protein detection are presented and
compared in Table 2.
After the confirmation of the IgG anchor and AGR2 protein detection onto the gold
surface, the transferability of the proposed substrate was examined on a biological sample
where AGR2 is present at low levels in crude lysates. For this experimental step, lysate
from A549 cells was chosen, which expresses AGR2 protein [35]. Negative controls of PBS
and medium containing lysis buffer were also evaluated. The samples’ incubations on the
Au/4-ATP/GA/aAGR2/BSA modified electrodes lasted 5 min and the unbound particles
were flushed away with deionized water. Next, the EIS spectra were recorded. For each
sample, a separate substrate was used. The complex detection with a mix of both positive
and negative samples on the same electrode was also examined.
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Table 2. The comparison of AGR2 proteindetection methods using electrochemical techniques on the various substrate.
Detection Substrate Target Molecules Turnaround Time Sensitivity Limit of Detection Reference
ITO
(CV, DPV, EIS) CA15-3 15 min 13 µL




activator receptor 35 s - 4.8 fM [40,41]
Polypyrrole-gold nanocomposite
(DPV) CA125 80 min - 30.9 ng/mL [42]
AuSPE
(EIS, DPV) MCF-7 91 s 77 EVs/mL 77 particles/mL [40,43]
SPCE
(CV, EIS) MUC1 45 min - 0.02 U/mL [40,44]
GCE
(DPV, Polylysine modification) AGR2 90 min - 2.3 fM [40,45]
GE
(DPV, AgNPs modification) AR-42 90 min - 6 cells/mL [40,46]
Au
(EIS) AGR2 3 min 127.5% (fg/mL)
−1 0.093 fg/mL this work
No crucial changes were observed for separate measurements of PBS and control
medium. The electrodes’ impedimetric characteristic stayed practically unchanged (Figure 5).
For the measurements of the mix of negative samples and lysate, representative data are
presented in Figure 5A, which shows impedance changes of the gold electrode during
the modification steps of the sensor and antigen detection. The substantial impedance
increase was observed after anti-AGR2 antibodies were linked and BSA free-sites were
blocked, confirming the presence of a densely packed protein biolayer. The incubation
of the Au/4-ATP/GA/aAGR2/BSA modified electrode with cell lysate A549 resulted in
successive impedance increases compared to the ready biosensor (Figure 5B). After the
AGR2 protein detection from the lysate, the same electrode was flushed with water and
incubated with PBS buffer to exclude unspecific interactions. The impedance decreased
slightly, which might be attributed to some disorder of the structure during electrode
displacement and rinsing. Most importantly, the Rct did not increase after incubation with
PBS, which would indicate false positive antibodies–antigen interactions.
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As further controls, Figure 5B highlights the impedance changes of the gold electrode
during modification steps of the sensor and antigen detection. This time, after proper
modification steps, the BSA saturated electrode was incubated with a negative control–
medium. An increase in impedance was observed, however negligible, compared to the
detection of the AGR2 protein in the lowest concentration of 0.01 fg/mL (Figure 5B). The
Rct value increased 57% (from 942.41 Ω to 1667.6 Ω). On the second step, the electrode was
rinsed with water and incubated again, this time with A549 cell lysate. The above results
confirmed the specificity of the developed sensor in the presence of negative buffers and
positive cell lysate samples. The detailed parameters for both sensors (Figures 5A and 4B)
with the chosen equivalent circuit were summarized in Table 1.
3.3. Biosensor Selectivity, Repeatability and Stability Studies
PBS, TBS, lysate buffer, and H1299 cells were used as negative samples to investigate
the selectivity of the immunosensor. As positive samples we used AGR2 protein and A549
cell lysates containing the AGR2 protein (Supplementary Figure S1). The negative samples’
concentration was kept in the same order of magnitude to receive comparable results. Next,
they were applied to the modified electrode separately. After 5 min incubation, the EIS
spectra were recorded. According to the assumptions, there was no significant increase in
the value of Rct parameter for the negative samples: PBS, TBS, lysate buffer, and H1299 cells.
Additionally, these changes did not exceed 10% (Figure 6). Compared to the %Rct change
in the presence of positive AGR2 protein and A549 cells, the negative samples were proved
to give no cross-reactivity, indicating that the proposed method has high selectivity for the
detection of protein AGR2. The percentage of changes in the charge transfer resistance
parameter for positive samples was noticeably larger and ranged from 117.11% to 124%. It
can be concluded from the measurements that the antibodies used in these studies properly
bind to each species of pathogen for which the sensor was designed. All measurements
were repeated on a series of three electrodes to confirm the lack of influence of negative
samples on further measurements. Furthermore, the relative standard deviations (RSD)
took values from 2 to 10%, which indicates the high stability of the proposed system.
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4. Conclusions
In summary, we have reported the extended investigation of an impedimetric im-
munosensor for AGR2 protein detection. The mechanism is based on the EIS spectra
recorded at antibody-modified gold electrodes. These data build on our prior research to
develop a gold electrode platform [33] but in this report we apply this to a monoclonal
antibody that targets a cancer antigen, AGR2. The obtained limit of detection (LOD) for
the presented immunosensor equals 0.093 fg/mL (S/N = 3). The advantage of this ‘one-
step’ diagnostic assay relative to an ELISA or mass spectrometry is rapid and sensitive
measurement of antigen binding. This provides a proof of concept that we intend to use to
develop clinical trials with plasma in order to determine whether AGR2 antigen detection
in patient fluid provides any prognostic indicator.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/bios11060184/s1, Figure S1: Immunohistochemical expression of AGR2 protein in A549
cells. The A549 cells were fixed with 4% (v/v) paraformaldehyde in PBS at RT for 15 min, washed
with PBS three times, and permeabilized using 0.25% triton X-100 in PBS at RT for 10 min. Then, the
cells were again washed with PBS three times and blocked with 3% BSA in PBS for 1 h. The primary
antibody was incubated at appropriate dilution (typically 1:1000) overnight at 4 ◦C. Alexa Fluor 488
goat anti-mouse (Invitrogen, USA) secondary antibody was incubated at RT for 1 h. Coverslips were
washed three times with PBS in between each step. Cells were incubated in DAPI (image B and
C) (Invitrogen, USA) diluted at 1:10,000 with dH2O for 5 min to stain the nucleus. An additional
3 washes with dH2O for 5 min were performed. A single drop of Fluorescence Mounting Medium
(S3023, Dako, Denmark) was used to mount the cells on the slide. The fluorescent signal (image A
and C) was detected using a Zeiss Axioplan 2 microscope (63× or 100× oil immersion objective).
Images were acquired by Micro-Manager 1.4 software. Images were processed in ImageJ 2.0 software.
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D.N.; formal analysis, B.V., R.O., and T.R.H. All authors have read and agreed to the published
version of the manuscript.
Funding: This work was supported with the European Regional Development Fund—Project
ENOCH (No. CZ.02.1.01/0.0/0.0/16_019/0000868), MH CZ—DRO (MMCI, 00209805); the BBSRC
RASOR consortium (BB/C511599/1; United Kingdom); The International Centre for Cancer Vaccine
Science project carried out within the International Research Agendas program of the Foundation
for Polish Science co-financed by the European Union under the European Regional Development
Fund TECHMATSTRATEG 1/347324/12/NCBR/2017. This research was funded by the First TEAM
program of the Foundation for Polish Science POIR.04.04.00-00-1644/18.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.
References
1. Aberger, F.; Weidinger, G.; Grunz, H.; Richter, K. Anterior Specification of Embryonic Ectoderm: The Role of the Xenopus Cement
Gland-Specific Gene XAG-2. Mech. Dev. 1998, 72, 115–130. [CrossRef]
2. Thompson, D.A.; Weigel, R.J. HAG-2, the Human Homologue of TheXenopus LaevisCement Gland Gene XAG-2, Is Coexpressed
with Estrogen Receptor in Breast Cancer Cell Lines. Biochem. Biophys. Res. Commun. 1998, 251, 111–116. [CrossRef]
3. Persson, S.; Rosenquist, M.; Knoblach, B.; Khosravi-Far, R.; Sommarin, M.; Michalak, M. Diversity of the Protein Disulfide
Isomerase Family: Identification of Breast Tumor Induced Hag2 and Hag3 as Novel Members of the Protein Family. Mol.
Phylogenet. Evol. 2005, 36, 734–740. [CrossRef]
4. Brychtova, V.; Mohtar, A.; Vojtesek, B.; Hupp, T.R. Mechanisms of Anterior Gradient-2 Regulation and Function in Cancer. Semin.
Cancer Biol. 2015, 33, 16–24. [CrossRef] [PubMed]
Biosensors 2021, 11, 184 10 of 11
5. Tian, S.; Tao, K.; Hu, J.; Liu, Z.; Ding, X.; Chu, Y.; Cui, J.; Shuai, X.; Gao, J.; Cai, K.; et al. The Prognostic Value of AGR2 Expression
in Solid Tumours: A Systematic Review and Meta-Analysis. Sci. Rep. 2017, 7, 15500. [CrossRef] [PubMed]
6. Sive, H.L.; Hattori, K.; Weintraub, H. Progressive Determination during Formation of the Anteroposterior Axis in Xenopus Laevis.
Cell 1989, 58, 171–180. [CrossRef]
7. Patel, P.; Clarke, C.; Barraclough, D.L.; Jowitt, T.A.; Rudland, P.S.; Barraclough, R.; Lian, L.-Y. Metastasis-Promoting Anterior
Gradient 2 Protein Has a Dimeric Thioredoxin Fold Structure and a Role in Cell Adhesion. J. Mol. Biol. 2013, 425, 929–943.
[CrossRef]
8. Kumar, A.; Godwin, J.W.; Gates, P.B.; Garza-Garcia, A.A.; Brockes, J.P. Molecular Basis for the Nerve Dependence of Limb
Regeneration in an Adult Vertebrate. Science 2007, 318, 772–777. [CrossRef]
9. Di Valentin, E.; Crahay, C.; Garbacki, N.; Hennuy, B.; Guéders, M.; Noël, A.; Foidart, J.-M.; Grooten, J.; Colige, A.; Piette, J.; et al.
New Asthma Biomarkers: Lessons from Murine Models of Acute and Chronic Asthma. Am. J. Physiol. Lung Cell Mol. Physiol.
2009, 296, L185–L197. [CrossRef] [PubMed]
10. Maurel, M.; Obacz, J.; Avril, T.; Ding, Y.-P.; Papadodima, O.; Treton, X.; Daniel, F.; Pilalis, E.; Hörberg, J.; Hou, W.; et al. Control of
Anterior GRadient 2 (AGR2) Dimerization Links Endoplasmic Reticulum Proteostasis to Inflammation. EMBO Mol. Med. 2019,
11. [CrossRef]
11. Fritzsche, F.R.; Dahl, E.; Pahl, S.; Burkhardt, M.; Luo, J.; Mayordomo, E.; Gansukh, T.; Dankof, A.; Knuechel, R.; Denkert, C.; et al.
Prognostic Relevance of AGR2 Expression in Breast Cancer. Clin. Cancer Res. 2006, 12, 1728–1734. [CrossRef] [PubMed]
12. Chanda, D.; Lee, J.H.; Sawant, A.; Hensel, J.A.; Isayeva, T.; Reilly, S.D.; Siegal, G.P.; Smith, C.; Grizzle, W.; Singh, R.; et al. Anterior
Gradient Protein-2 Is a Regulator of Cellular Adhesion in Prostate Cancer. PLoS ONE 2014, 9, e89940. [CrossRef] [PubMed]
13. Dumartin, L.; Alrawashdeh, W.; Trabulo, S.M.; Radon, T.P.; Steiger, K.; Feakins, R.M.; di Magliano, M.P.; Heeschen, C.; Esposito, I.;
Lemoine, N.R.; et al. ER Stress Protein AGR2 Precedes and Is Involved in the Regulation of Pancreatic Cancer Initiation. Oncogene
2017, 36, 3094–3103. [CrossRef]
14. Lepreux, S.; Bioulac-Sage, P.; Chevet, E. Differential Expression of the Anterior Gradient Protein-2 Is a Conserved Feature during
Morphogenesis and Carcinogenesis of the Biliary Tree. Liver Int. 2011, 31, 322–328. [CrossRef] [PubMed]
15. Gray, T.A.; MacLaine, N.J.; Michie, C.O.; Bouchalova, P.; Murray, E.; Howie, J.; Hrstka, R.; Maslon, M.M.; Nenutil, R.; Vojtesek, B.;
et al. Anterior Gradient-3: A Novel Biomarker for Ovarian Cancer That Mediates Cisplatin Resistance in Xenograft Models. J.
Immunol. Methods 2012, 378, 20–32. [CrossRef]
16. Pohler, E.; Craig, A.L.; Cotton, J.; Lawrie, L.; Dillon, J.F.; Ross, P.; Kernohan, N.; Hupp, T.R. The Barrett’s Antigen Anterior
Gradient-2 Silences the P53 Transcriptional Response to DNA Damage. Mol. Cell Proteom. 2004, 3, 534–547. [CrossRef]
17. O’Neill, J.R.; Pak, H.-S.; Pairo-Castineira, E.; Save, V.; Paterson-Brown, S.; Nenutil, R.; Vojtěšek, B.; Overton, I.; Scherl, A.; Hupp,
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37. Cebula, Z.; Żołędowska, S.; Dziąbowska, K.; Skwarecka, M.; Malinowska, N.; Białobrzeska, W.; Czaczyk, E.; Siuzdak, K.; Sawczak,
M.; Bogdanowicz, R.; et al. Detection of the Plant Pathogen Pseudomonas Syringae Pv. Lachrymans on Antibody-Modified Gold
Electrodes by Electrochemical Impedance Spectroscopy. Sensors 2019, 19, 5411. [CrossRef]
38. Niedzialkowski, P.; Slepski, P.; Wysocka, J.; Chamier-Cieminska, J.; Burczyk, L.; Sobaszek, M.; Wcislo, A.; Ossowski, T.;
Bogdanowicz, R.; Ryl, J. Multisine Impedimetric Probing of Biocatalytic Reactions for Label-Free Detection of DEFB1 Gene: How
to Verify That Your Dog Is Not Human? Sens. Actuators B Chem. 2020, 323, 128664. [CrossRef]
39. Augustine, S.; Kumar, P.; Malhotra, B.D. Amine-Functionalized MoO3@RGO Nanohybrid-Based Biosensor for Breast Cancer
Detection. ACS Appl. Biol. Mater. 2019, 2, 5366–5378. [CrossRef]
40. Gajdosova, V.; Lorencova, L.; Kasak, P.; Tkac, J. Electrochemical Nanobiosensors for Detection of Breast Cancer Biomarkers.
Sensors 2020, 20, 4022. [CrossRef]
41. Roberts, A.; Tripathi, P.P.; Gandhi, S. Graphene Nanosheets as an Electric Mediator for Ultrafast Sensing of Urokinase Plasminogen
Activator Receptor-A Biomarker of Cancer. Biosens. Bioelectron. 2019, 141, 111398. [CrossRef] [PubMed]
42. Negahdary, M. Aptamers in Nanostructure-Based Electrochemical Biosensors for Cardiac Biomarkers and Cancer Biomarkers: A
Review. Biosens. Bioelectron. 2020, 152, 112018. [CrossRef]
43. Kilic, T.; Valinhas, A.T.D.S.; Wall, I.; Renaud, P.; Carrara, S. Label-Free Detection of Hypoxia-Induced Extracellular Vesicle
Secretion from MCF-7 Cells. Sci. Rep. 2018, 8, 9402. [CrossRef]
44. Nawaz, M.A.H.; Rauf, S.; Catanante, G.; Nawaz, M.H.; Nunes, G.; Marty, J.L.; Hayat, A. One Step Assembly of Thin Films of
Carbon Nanotubes on Screen Printed Interface for Electrochemical Aptasensing of Breast Cancer Biomarker. Sensors 2016, 16,
1651. [CrossRef] [PubMed]
45. Luo, L.; Wang, L.; Zeng, L.; Wang, Y.; Weng, Y.; Liao, Y.; Chen, T.; Xia, Y.; Zhang, J.; Chen, J. A Ratiometric Electrochemical DNA
Biosensor for Detection of Exosomal MicroRNA. Talanta 2020, 207, 120298. [CrossRef]
46. Tang, Y.; Dai, Y.; Huang, X.; Li, L.; Han, B.; Cao, Y.; Zhao, J. Self-Assembling Peptide-Based Multifunctional Nanofibers for
Electrochemical Identification of Breast Cancer Stem-like Cells. Anal. Chem. 2019, 91, 7531–7537. [CrossRef]
